1. Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands.
- Author
-
Bennink C, Brink M, Duijts SFA, Scheurer H, Sonneveld P, and Blommestein HM
- Subjects
- Humans, Netherlands, Female, Male, Middle Aged, Aged, Adult, Multiple Myeloma therapy, Multiple Myeloma economics, Multiple Myeloma diagnosis, Multiple Myeloma mortality, Employment statistics & numerical data, Income
- Abstract
Objective: Due to new treatment options, survival rates in multiple myeloma (MM) are improving. Consequently, maintaining work and income is becoming more important for patients and society. Therefore, we aimed to explore the change in income and employment in patients with MM., Methods: Data from the Netherlands Cancer Registry of MM patients diagnosed between 2012 and 2017 were merged with socioeconomic data from Statistics Netherlands. Descriptive statistics were used to analyse total income, income from employment, and accumulated income before and after diagnosis., Results: Income from employment decreased by 45% in MM patients, between 1 year before and 4 years after diagnosis Four years after diagnosis, 35% of the patients were still employed, with an accumulated 5-year productivity loss of €121 million. Higher income loss from employment and job loss was observed in female patients, patients with more extensive disease, or those not treated with autologous stem cell transplant., Conclusion: Loss of (income from) employment among patients with MM was high, causing financial burden on the patient and society. With improving survival in MM, more research and awareness are needed to better assess the importance of income and work for MM patients and society., Competing Interests: Disclosure PS: Received Research grants from Amgen, Celgene, Janssen, Skyline Dx. Honoraria from Amgen, Celgene, Janssen, Karyopharm, Seagen, Skyline Dx. HB Reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). CB, MB, HS, SD: None., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF